SHOULDER APPLICATIONS

Whether you are addressing damaged tissue in an articular cartilage, rotator cuff, labrum, or surrounding soft tissue; consider Wharton’s jelly for Connective Tissue Supplementation to repair or replace the damaged tissue with new healthy connective tissue.

Contact Us
arrow
shoulder

Tissue damage may be the root of the problem for many patients dealing with shoulder issues.

Are you looking for an option to address tissue damage in your shoulder? CryoText for homologous orthopedic shoulder applications is the place to begin.

Wharton’s jelly for Connective Tissue Supplementation to repair or replace damaged tissue is the new standard of care.

Wharton’s jelly allografts consist of donated human umbilical cord tissue that is disassociated, suspended in saline, and cryopreserved. Intended for homologous use only, their primary function is to provide cushioning and structural support and replace missing or damaged tissue in the patient, applied directly to the defect or injured area in soft tissues. The allografts are applied via syringe and are typically used in ligament, muscle, or cartilage tears. 

Regenative Labs’ resources are divided into the following categories:

Discovery icon - magnifying glass

Discover

Discover our catalogue of applications showcasing how Regenative Labs’ proprietary products can be used.

View all Applications
arrow
Study Icon - microscope

STUDY

Study the latest innovations and the variety of options available to medical specialties.

View Publications
arrow
Explore icon - DNA and magnifying glass

EXPLORE

Explore the detailed descriptions of our products, their make-up and development through our state-of-the-art process and to identify which products are best suited for your patients’ unique needs.

VIEW ALL PRODUCTS
arrow

Commitment to Quality and Transparency

Regenative Labs is a leader in the field of regenerative medicine. Our commitment to quality and transparency is demonstrated by collecting data from patient outcomes and analyzing it for statistical significance, ensuring physicians make the most informed decision to facilitate the best possible outcomes for their patients.

From our retrospective data repository, you will witness improvements beginning at the 30-day mark.

DATA

Data Collection Protocol Approved by the Institute of Regenerative and Cellular Medicine (IRB)

shoulder
improvements in nprs and womac

Data ranges chart

Shoulders Data ranges chart

This data is based on a sample of 143 patients with structural shoulder defects from 38 different clinics enrolled in our observational study. There are 80 males and 63 females, aged 36 to 89. Ninety days after the Wharton’s jelly application, patients reported a 39% improvement in NPRS (current pain) and a 35% overall WOMAC improvement (pain/ stiffness/ function). The progress shown is from only one application, although most care providers apply two Wharton’s jelly allografts for this area.  

PUBLISHED OBSERVATIONAL STUDY

Demonstrates the safety and efficacy of Wharton’s Jelly Tissue Allogfrafts for Rotator Cuff Tears

read the observational study

Our shared goal is to address the root cause of the problem for patients in debilitating situations and partner to offer an effective and minimally-invasive option.

You know the vital role tissue health plays in the overall well-being of patients. Regenative Labs’ mission is to facilitate predictable patient outcomes by offering the highest quality human tissue allografts available.

Contact Us
arrow

Improving Quality of Life

When we experience pain, our body sends a message that something is wrong. Pain is merely a symptom of an underlying injury. Using steroids or opiates alone to address pain caused by injury masks the issue instead of addressing the root cause.

With connective tissue supplementation, medical providers have an opportunity to address the problem at its source by inserting new, viable connective tissue ECM directly to the site of the breakdown, or defect (via syringe). The patient’s body can use the collagenic superstructure from the newly transplanted Wharton’s jelly as building blocks to fill voids or defects in cartilage beds or other soft tissues.

LEARN About Wharton’s Jelly

About Wharton’s Jelly

Wharton’s Jelly (WJ) was initially characterized in 1656 by Thomas Wharton[1]. Advances in regenerative medicine have increased significantly throughout the past decade. Located between the blood vessels of the umbilical cord and the amniotic epithelium, WJ spans the entire length of the umbilical cord, providing protection, cushioning, and structural support [2,3].

read research article

Since its initial discovery, there has been significant interest in the use of WJ in regenerative medicine applications[2].

Initial research centered on WJ as a cellular product, dependent on the metabolic activity of living cells to exert its primary function[3]. However, current research demonstrates that WJ exerts an effect independent of any cellular activity[3]. Initially classified as a mucoid connective tissue, we now know that WJ functions as an ideal system to transplant chemokine and growth factors, in addition to providing a biomechanical microarchitecture for collagen extracellular matrix formation in collagen-based defects[4].

ADVANTAGES OF WHARTON’S JELLY

This connective tissue contains high amounts of extracellular matrix components including collagen types I, III, and V, elastin, and fibronectin [1, 2]. Wharton’s jelly mainly provides cushioning and structural support to the umbilical cord but also contains a natural source of long-chain hyaluronic acid and numerous cytokines and growth factors. Studies have described placental tissues to be “immune privileged” as they rarely evoke an immune response in the body, reducing the risk of adverse reactions [4].

Structural Support

Wharton’s jelly provides a natural scaffold to facilitate cellular adhesion [1, 2].

CITATIONS:

1. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013 May 31;14(6):11692-712. doi: 10.3390/ijms140611692. PMID: 23727936; PMCID: PMC3709752.

2. Gupta A, El-Amin SF 3rd, Levy HJ, Sze-Tu R, Ibim SE, Maffulli N. Umbilical cord derived Wharton’s jelly for regenerative medicine applications. J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. PMID: 32054483; PMCID: PMC7017504.

3. Deus IA, Mano JF, Custódio CA. Perinatal tissues and cells in tissue engineering and regenerative medicine. Acta Biomater. 2020 Jul 1;110:1-14. doi: 10.1016/j. actbio.2020.04.035. Epub 2020 May 14. PMID: 32418650.

4. Jadalannagari S, Converse G, McFall C, Buse E, Filla M, Villar MT, Artigues A, MellotAJ, Wang J, Detamore MS, Hopkins RA, Aljitawi OS. Decellularized Wharton’s Jelly from human umbilical cord as a novel 3D scaffolding material for tissue engineering applications. PLoS One. 2017 Feb 21;12(2):e0172098. doi: 10.1371/journal. pone.0172098. Erratum in: PLoS One. 2017 Mar 7;12 (3):e0173827. PMID: 28222169; PMCID: PMC5319682.

CryoText Product Information

For more information about our Cryotext product, visit the link below.

Pricing and PLACING AN order

For pricing or to place an order, login or setup an account to get immediate access to our MEDNGINE platform.

DON’t HESITATE TO REACH OUT.

If you have any further questions, please contact us. We look forward to speaking with you!

CODE LIST

Download the ICD-10 Code List to Identify Other Potential Use Sites.